The Marcus Center for Therapeutic Cell Characterization and Manufacturing (MC3M) at the Georgia Institute of Technology is excited to officially welcome Johnna Temenoff as the center’s new director. MC3M brings together clinicians, industry researchers, and product developers with scientists and engineers of multiple disciplines to tackle the challenge of highly controlled, well-characterized, efficient, reproducible, and high-quality cell manufacturing. 

“I am extremely honored to be named the director of the Marcus Center for Therapeutic Cell Characterization and Manufacturing,” said Temenoff. “The Center has demonstrated significant and sustained impact on the field of cell manufacturing since its founding in 2016, and along with our NSF ERC on Cell Manufacturing Technologies, has positioned Georgia Tech on the cutting edge of technologies to improve quality and affordability of cell-based therapeutics.”

Temenoff joined the Coulter Department of Biomedical Engineering (BME) at Georgia Tech/Emory University in 2005 and is currently the Carol Ann and David D. Flanagan Professor in BME. She also currently serves as the director of the NSF Engineering Research Center in Cell Manufacturing Technologies (CMaT). Temenoff has received several awards and honors for her work in scaling culture of therapeutic cells and biomaterials for regenerative medicine applications. These include the Society for Biomaterials (SFB) Clemson Award for Contributions to the Literature, College of Fellows of the American Institute for Medical and Biological Engineers (AIMBE), Fellow of the Biomedical Engineering Society (BMES), Fellow of the International Academy of Medical and Biological Engineering (IAMBE) and Fellow of Biomaterials Science and Engineering, International Union of Societies for Biomaterials Science and Engineering (IUSBSE). 

Temenoff is preceded by Krishnendu “Krish” Roy, professor in the Coulter Department of Biomedical Engineering. In August, Roy left Georgia Tech/Emory to begin a leadership position at Vanderbilt University as Dean of Engineering. 

“I am particularly excited to be taking on a leadership role in MC3M at this time as the field has grown tremendously in the past five-plus years. The types of tools and technologies we are developing are increasingly important to assure that advanced biotherapeutics are available to all who need them,” stated Temenoff.

In the news Thumbnail
Johnna Temenoff…